Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18

NCT06347627 | Enrolling By Invitation

• 1 other identifier: UW23139
• Study Type: interventional
• Target: 1,600
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to comprehensively assess confidence in and acceptance of human papillomavirus (HPV) vaccines among Japanese parents and caregivers with daughters aged 12-18 and their decision-making process.

Conditions

Healthy

Keywords

HPV Vaccine

Outcome Measures

Primary Outcomes (1)

• Willingness to receive HPV vaccines for daughters

  A degree of a change in willingness to receive HPV vaccines after viewing an experimental message will be scored on a 5-point scale. The options are 1) much less willing to get the HPV vaccine for my daughter, 2) somewhat less, 3) neither more or less, 4) somewhat more, and 5) much more, with higher scores indicating a better outcome.

  This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.

Secondary Outcomes (1)

• Confidence in HPV vaccine safety

  This experiment is expected to take 20-30 minutes to complete. The study will assess the outcome measure immediately after participants are exposed to the experimental messages.

Study Arms (16)

Group 1 (I x S x S x F)

EXPERIMENTAL

Participants in Group 1 will view a message in an X (former Twitter) format composed of "Individual x Safety x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 1 (I x S x S x F)

Group 2 (O x S x S x F)

EXPERIMENTAL

Participants in Group 2 will view a message in an X (former Twitter) format composed of "Organization x Safety x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 2 (O x S x S x F)

Group 3 (I x E x S x F)

EXPERIMENTAL

Participants in Group 3 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 3 (I x E x S x F)

Group 4 (O x E x S x F)

EXPERIMENTAL

Participants in Group 4 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Storytelling x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 4 (O x E x S x F)

Group 5 (I x S x S x M)

EXPERIMENTAL

Participants in Group 5 will view a message in an X (former Twitter) format composed of "Individual x Safety x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 5 (I x S x S x M)

Group 6 (O x S x S x M)

EXPERIMENTAL

Participants in Group 6 will view a message in an X (former Twitter) format composed of "Organization x Safety x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 6 (O x S x S x M)

Group 7 (I x E x S x M)

EXPERIMENTAL

Participants in Group 7 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 7 (I x E x S x M)

Group 8 (O x E x S x M)

EXPERIMENTAL

Participants in Group 8 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Storytelling x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 8 (O x E x S x M)

Group 9 (I x S x D x F)

EXPERIMENTAL

Participants in Group 9 will view a message in an X (former Twitter) format composed of "Individual x Safety x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 9 (I x S x D x F)

Group 10 (O x S x D x F)

EXPERIMENTAL

Participants in Group 10 will view a message in an X (former Twitter) format composed of "Organization x Safety x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 10 (O x S x D x F)

Group 11 (I x E x D x F)

EXPERIMENTAL

Participants in Group 11 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 11 (I x E x D x F)

Group 12 (O x E x D x F)

EXPERIMENTAL

Participants in Group 12 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Scientific data x Factual" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 12 (O x E x D x F)

Group 13 (I x S x D x M)

EXPERIMENTAL

Participants in Group 13 will view a message in an X (former Twitter) format composed of "Individual x Safety x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 13 (I x S x D x M)

Group 14 (O x S x D x M)

EXPERIMENTAL

Participants in Group 14 will view a message in an X (former Twitter) format composed of "Organization x Safety x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 14 (O x S x D x M)

Group 15 (I x E x D x M)

EXPERIMENTAL

Participants in Group 15 will view a message in an X (former Twitter) format composed of "Individual x Effectiveness x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 15 (I x E x D x M)

Group 16 (O x E x D x M)

EXPERIMENTAL

Participants in Group 16 will view a message in an X (former Twitter) format composed of "Organization x Effectiveness x Scientific data x Misinformation" factors. The message will be available for participants to view while answering five questions that evaluate how it influenced caregivers' trust, confidence, and motivation to vaccinate.

Behavioral: Group 16 (O x E x D x M)

Interventions

Group 1 (I x S x S x F) BEHAVIORAL

Experimental message: Individual x Safety x Storytelling x Factual

Group 1 (I x S x S x F)

Group 2 (O x S x S x F) BEHAVIORAL

Experimental message: Organization x Safety x Storytelling x Factual

Group 2 (O x S x S x F)

Group 3 (I x E x S x F) BEHAVIORAL

Experimental message: Individual x Effectiveness x Storytelling x Factual

Group 3 (I x E x S x F)

Group 4 (O x E x S x F) BEHAVIORAL

Experimental message: Organization x Effectiveness x Storytelling x Factual

Group 4 (O x E x S x F)

Group 5 (I x S x S x M) BEHAVIORAL

Experimental message: Individual x Safety x Storytelling x Misinformation

Group 5 (I x S x S x M)

Group 6 (O x S x S x M) BEHAVIORAL

Experimental message: Organization x Safety x Storytelling x Misinformation

Group 6 (O x S x S x M)

Group 7 (I x E x S x M) BEHAVIORAL

Experimental message: Individual x Effectiveness x Storytelling x Misinformation

Group 7 (I x E x S x M)

Group 8 (O x E x S x M) BEHAVIORAL

Experimental message: Organization x Effectiveness x Storytelling x Misinformation

Group 8 (O x E x S x M)

Group 9 (I x S x D x F) BEHAVIORAL

Experimental message: Individual x Safety x Scientific data x Factual

Group 9 (I x S x D x F)

Group 10 (O x S x D x F) BEHAVIORAL

Experimental message: Organization x Safety x Scientific data x Factual

Group 10 (O x S x D x F)

Group 11 (I x E x D x F) BEHAVIORAL

Experimental message: Individual x Effectiveness x Scientific data x Factual

Group 11 (I x E x D x F)

Group 12 (O x E x D x F) BEHAVIORAL

Experimental message: Organization x Effectiveness x Scientific data x Factual

Group 12 (O x E x D x F)

Group 13 (I x S x D x M) BEHAVIORAL

Experimental message: Individual x Safety x Scientific data x Misinformation

Group 13 (I x S x D x M)

Group 14 (O x S x D x M) BEHAVIORAL

Experimental message: Organization x Safety x Scientific data x Misinformation

Group 14 (O x S x D x M)

Group 15 (I x E x D x M) BEHAVIORAL

Experimental message: Individual x Effectiveness x Scientific data x Misinformation

Group 15 (I x E x D x M)

Group 16 (O x E x D x M) BEHAVIORAL

Experimental message: Organization x Effectiveness x Scientific data x Misinformation

Group 16 (O x E x D x M)

Eligibility Criteria

• Age: 20 Years+
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female adult caregivers, older than 20, with daughters aged 12-18 who have received none or only one shot of HPV vaccine.

You may not qualify if:

• Caregivers who do not agree to participate in survey, experiment, or both.
• Caregivers with daughters who have already received two or more HPV vaccines.

Sponsors & Collaborators

• The University of Hong Kong: lead
• London School of Hygiene and Tropical Medicine: collaborator
• Nagasaki University: collaborator

Study Sites (1)

London School of Hygiene and Tropical Medicine

London, United Kingdom

Location

Related Publications (1)

• Kobayashi K, Masuda K, Wu JT, Lin L. Impact of digital communication message on HPV vaccine decision-making among Japanese mothers: A randomized controlled trial. Vaccine. 2025 Aug 13;61:127327. doi: 10.1016/j.vaccine.2025.127327. Epub 2025 Jun 3.

  PMID: 40466485 DERIVED

Study Officials

• Leesa Lin, PhD

  London School of Hygiene and Tropical Medicine

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: FACTORIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 17, 2024
• First Posted: April 4, 2024
• Study Start: December 22, 2023
• Primary Completion: December 1, 2024
• Study Completion: December 1, 2024
• Last Updated: April 4, 2024

Record last verified: 2024-03

Locations

GB (1)